2024
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa S, Jansen C, Jani Y, Evans S, Zhuang T, Brown J, Nazha B, Master V, Bilen M. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker Insights 2024, 19: 11772719241254179. PMID: 38827239, PMCID: PMC11143877, DOI: 10.1177/11772719241254179.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsResponse to immunotherapyAdverse eventsTreatment of genitourinary malignanciesImmune checkpoint blockadeSelection of therapySignificant side effectsCheckpoint blockadeCheckpoint inhibitorsGU malignanciesGenitourinary malignanciesPatient tumorsTreatment landscapeReview of biomarkersGenitourinary cancersGU tumorsPreclinical studiesPrognostic toolSide effectsTherapyBiomarker developmentTumorPatientsImmunotherapy
2022
Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.
Labaki C, Schmidt A, Bakouny Z, Labban M, Zarif T, Chang S, McGregor B, Kibel A, Rebbeck T, Trinh Q, Choueiri T. Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic. Journal Of Clinical Oncology 2022, 40: 281-281. DOI: 10.1200/jco.2022.40.6_suppl.281.Peer-Reviewed Original ResearchRenal cell carcinomaGU malignanciesUrothelial carcinomaProstate cancerSurgical treatmentCancer screeningGenitourinary (GU) malignanciesTriaging of carePSA screeningCell carcinomaCystectomy proceduresManagement modalitiesCOVID-19 pandemicMalignancyIncreased MortalityDiagnosisProgressive recoveryCancerEvaluate screeningCarcinomaHealthcare servicesHealthcare systemTreatmentPre-pandemic periodCOVID-19
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply